左心房与心室应变评估的逆重构反映沙库巴曲/缬沙坦治疗反应
本研究为回顾性队列,纳入409例射血分数降低的心力衰竭(HFrEF)患者(共1258次超声心动图),分析接受沙库巴曲/缬沙坦治疗后左心室整体纵向应变(LVGLS)与左心房储存应变(LARS)的时间轨迹。中位随访27.1个月,LVGLS与LARS在治疗6个月内显著改善,完全左心逆重构(LVGLS改善至≥13%且LARS改善至≥12.5%)与较低的心血管死亡和心衰住院风险显著相关,且强于其他常规超声参数的变化。
要点
- HFrEF患者接受沙库巴曲/缬沙坦治疗后,LVGLS与LARS在6个月内改善最明显。
- LVGLS改善至≥13%且LARS改善至≥12.5%定义完全左心逆重构,与预后改善相关。
- 应变指标改善对治疗反应的反映强于常规超声参数变化。
核心结论
- 在HFrEF患者中,沙库巴曲/缬沙坦治疗可改善LVGLS和LARS,通常出现在治疗6个月内;由LVGLS和LARS改善定义的完全左心逆重构可作为治疗反应和预后的指标。
研究设计与样本
- 回顾性队列研究,纳入409例接受沙库巴曲/缬沙坦处方的HFrEF患者,共1258次超声心动图,中位随访27.1个月(IQR:18.3-36.3个月)。
关键影像表现/征象
- LVGLS在治疗6个月内从10.2%(IQR:7.9%-12.7%)改善至13.9%(IQR:10.5%-16.3%)(P < 0.001)。
- LARS在治疗6个月内从11.4%(IQR:8.4%-15.6%)改善至15.9%(IQR:11.5%-21.4%)(P < 0.001)。
- 未发生研究结局的患者中LVGLS和LARS改善幅度大于发生事件的患者。
诊断标准与关键数值
- 完全左心逆重构定义为LVGLS改善至≥13%且LARS改善至≥12.5%。
- 完全左心逆重构与较低的心血管死亡和心衰住院风险显著相关,该关联强于其他常规超声心动图参数的变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: The left ventricular global longitudinal strain (LVGLS) and left atrial reservoir strain (LARS) are considered as sensitive and reliable markers of cardiac remodeling and function. However, their temporal changes during optimal management of heart failure with reduced ejection fraction (HFrEF) are unknown.
OBJECTIVES: This study investigated the time trajectories of the LARS and LVGLS in patients with HFrEF treated with angiotensin receptor-neprilysin inhibitors, and assessed whether the LARS and LVGLS could define left heart reverse remodeling (LHRR) and reflect the treatment response and prognosis.
METHODS: Using a retrospective cohort of patients with HFrEF prescribed sacubitril/valsartan, we assessed the time trajectories of the LVGLS and LARS in 409 patients (1,258 echocardiograms), and investigated their association with the occurrence of cardiovascular death and hospitalization for heart failure (HHF), after the determination of LHRR, during a median follow-up of 27.1 (IQR: 18.3-36.3) months.
RESULTS: Among patients with HFrEF prescribed sacubitril/valsartan, both the LVGLS and LARS improved over time. The improvements in the LVGLS and LARS were prominent within 6 months of sacubitril/valsartan treatment: the LVGLS improved from 10.2% (IQR: 7.9%-12.7%) to 13.9% (IQR: 10.5%-16.3%) (P < 0.001), and the LARS improved from 11.4% (IQR: 8.4%-15.6%) to 15.9% (IQR: 11.5%-21.4%) (P < 0.001). These improvements were larger among patients who did not experience the study outcome than in patients with events. Improvement in the LVGLS to ≥13% and LARS to ≥12.5% (ie, complete LHRR) was significantly associated with a lower risk of cardiovascular death and HHF, and this association was stronger than that of changes in other conventional echocardiographic parameters.
CONCLUSIONS: In patients with HFrEF treated with sacubitril/valsartan, the LVGLS and LARS were improved, typically within 6 months of treatment. Complete LHRR, defined by improvement in the LVGLS and LARS, can be an indicator of treatment response and prognosis.
引用
- Moon MG, Hwang IC, Lee HJ, et al. Reverse Remodeling Assessed by Left Atrial and Ventricular Strain Reflects Treatment Response to Sacubitril/Valsartan. JACC Cardiovasc Imaging. 2022. PMID: 36075612. doi:10.1016/j.jcmg.2022.03.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。